PolyPid Ltd. (PYPD)
NASDAQ:PYPD
Top Page
PolyPid
(NASDAQ:PYPD)
Select Model
Select Model
Rating:56Neutral
Price Target:
$4.50
▲(4.90% Upside)
Action:ReiteratedDate:12/30/25
The score is held back primarily by weak financial fundamentals (no revenue, continued losses/cash burn, and financing risk). Offsetting this is a favorable earnings-call outlook with clear regulatory timelines and commercial readiness progress, while technicals show an uptrend but appear overbought. Valuation is difficult to anchor given negative earnings and no dividend.
Positive Factors
Clinical Trial Progress
The positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.
Negative Factors
Consistent Financial Losses
Ongoing financial losses highlight challenges in achieving profitability, which could impact long-term sustainability and require continued external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Progress
The positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.
Read all positive factors
PolyPid (PYPD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$81.87M
Dividend YieldN/A
Average Volume (3M)72.46K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth61.23%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding19,083,237
10 Day Avg. Volume44,210
30 Day Avg. Volume72,461
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)6.47
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$11.00Price Target Upside156.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$850.00K
PolyPid Business Overview & Revenue Model
Company Description
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phas...
How the Company Makes Money
PolyPid generates revenue primarily through the development and commercialization of its proprietary PLEX technology, which facilitates the extended release of drugs at surgical sites. The company's revenue model is focused on advancing its produc...
PolyPid Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and regulatory momentum: positive Phase III results, clear FDA pre‑NDA agreement, an imminent rolling NDA submission, advanced U.S. partner discussions, and a strategic technology expansion (Kynatrix and GLP‑1 program). These operational highlights position the company for a potential transformative 2026. However, material lowlights include a limited cash runway into H2 2026, rising operating expenses and an increased full‑year net loss, as well as dependence on partnership execution and a likely multi‑month adoption curve post‑approval. Overall the positive regulatory and clinical milestones significantly outweigh the financial and execution risks, but those risks will require near‑term resolution.Positive Updates
Phase III Success and Clinical Validation
Completed SHIELD II Phase III trial; D-PLEX100 met its primary endpoint and all key secondary endpoints, demonstrating a meaningful reduction in surgical site infections. External clinical engagement (KOL webinar with Dr. Steven D. Wexner) reinforced trial design and real-world relevance.
Negative Updates
Limited Cash Runway and Financing Risk
Cash and equivalents were $12.9M at Dec 31, 2025; subsequent warrant exercises added $3.7M in gross proceeds. Management estimates runway into the second half of 2026, creating dependency on partnerships, milestone payments or additional financing to support commercialization and longer‑term operations.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase III Success and Clinical Validation
Completed SHIELD II Phase III trial; D-PLEX100 met its primary endpoint and all key secondary endpoints, demonstrating a meaningful reduction in surgical site infections. External clinical engagement (KOL webinar with Dr. Steven D. Wexner) reinforced trial design and real-world relevance.
Read all positive updates
Company Guidance
Management guided that it expects to begin a rolling NDA submission for D‑PLEX100 by the end of Q1 2026—submitting the CMC/nonclinical module first and the clinical module within a couple of months—with Fast Track/breakthrough support and an anticipated priority review of ~6 months (vs. ~10 months standard); a European filing is planned roughly one quarter after the FDA submission. The company reiterated its targeted initial label for prevention of surgical site infections in abdominal colorectal surgery with potential for broader abdominal expansion, said U.S. commercial partner discussions are in advanced, operational due diligence, and noted uptake will likely take a few months post‑approval but become sticky once on formulary. Financially, PolyPid had $12.9M in cash, cash equivalents and short‑term deposits at 12/31/2025 plus $3.7M of subsequent warrant exercise proceeds (exercise prices $3.61–$4.50) and believes existing resources will fund operations into the second half of 2026; FY‑2025 P&L metrics included R&D $23.8M (Q4 $6.2M), G&A $7.2M (Q4 $1.8M), marketing/business development $2.0M (Q4 $0.6M), and a FY net loss of $34.2M or $2.09/share (Q4 net loss $8.5M or $0.41/share). Management also highlighted Kynatrix expansion plans (e.g., an ultra‑long‑acting GLP‑1 program targeting ~60‑day exposure) with additional preclinical data expected mid‑year.PolyPid Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -1.72M | -1.12M |
| EBITDA | -31.86M | -26.41M | -21.05M | -36.37M | -41.48M |
| Net Income | -34.17M | -29.02M | -23.86M | -39.52M | -40.71M |
Balance Sheet | |||||
| Total Assets | 22.31M | 25.22M | 15.37M | 25.97M | 44.23M |
| Cash, Cash Equivalents and Short-Term Investments | 12.93M | 15.64M | 5.61M | 12.59M | 32.20M |
| Total Debt | 2.80M | 9.62M | 11.78M | 13.73M | 0.00 |
| Total Liabilities | 11.33M | 17.54M | 17.47M | 20.14M | 8.28M |
| Stockholders Equity | 10.97M | 7.68M | -2.10M | 5.83M | 35.96M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -22.04M | -17.43M | -36.08M | -35.38M |
| Operating Cash Flow | 0.00 | -21.96M | -17.24M | -34.32M | -32.39M |
| Investing Cash Flow | 0.00 | -330.00K | 3.80M | 16.57M | 36.90M |
| Financing Cash Flow | 0.00 | 32.42M | 9.98M | 16.43M | 1.03M |
PolyPid Technical Analysis
Positive
4.29
Price Trends
4.41
Negative
4.19
Positive
3.82
Positive
Market Momentum
-0.04
Positive
49.65
Neutral
19.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYPD, the sentiment is Positive. The current price of 4.29 is above the 20-day moving average (MA) of 4.27, below the 50-day MA of 4.41, and above the 200-day MA of 3.82, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.65 is Neutral, neither overbought nor oversold. The STOCH value of 19.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PYPD.
PolyPid Risk Analysis
PolyPid disclosed 78 risk factors in its most recent earnings report. PolyPid reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PolyPid Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $81.87M | -2.64 | -291.42% | ― | ― | 61.23% | |
52 Neutral | $19.72M | -0.14 | -380.13% | ― | ― | 54.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $16.11M | -0.51 | -54.40% | ― | ― | 18.73% | |
50 Neutral | $194.63M | 5.44 | -21.16% | ― | -92.42% | 62.37% |
* Healthcare Sector Average
PYPD
PolyPid
4.29
1.54
56.00%
CTXR
Citius Pharmaceuticals
0.72
-0.64
-47.06%
SABS
SAB Biotherapeutics
3.82
2.29
149.67%
LIMN
Liminatus Pharma
0.20
-14.81
-98.70%
TAOX
Tao Synergies
6.28
3.65
138.78%
APLM
Apollomics
17.87
9.71
119.00%
PolyPid Corporate Events
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation
Dec 31, 2025
On December 31, 2025, PolyPid Ltd. reported that it has convened an Extraordinary General Meeting of Shareholders to be held on February 4, 2026, at its Petach Tikva headquarters, with a single agenda item: approval of the compensation terms of Ms...
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth
Dec 16, 2025
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. With over 25 years of MedTech leadership experience, including senior roles at Becton, Dickinson and Company and Medtronic P...
PolyPid Gains FDA Support for D-PLEX100 NDA Submission
Dec 3, 2025
On December 3, 2025, PolyPid announced receiving positive feedback from the FDA regarding its pre-NDA meeting for D-PLEX100, a product designed to prevent surgical site infections. The FDA’s agreement on the adequacy of PolyPid’s clini...
PolyPid Expands Share Offering to Strengthen Financial Position
Nov 26, 2025
On November 26, 2025, PolyPid Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares from $8,250,000 to $15,000,000 under its Sales Agreement with Oppenheimer Co. Inc. This strategic financial move is aimed at b...
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
Nov 12, 2025
PolyPid Ltd. announced its third-quarter 2025 financial results and provided a corporate update, highlighting significant advancements in its regulatory strategy and commercial readiness for D-PLEX₁₀₀. The company is preparing fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.